Yıl: 2019 Cilt: 18 Sayı: 1 Sayfa Aralığı: 30 - 33 Metin Dili: İngilizce DOI: 10.4274/uob.galenos.2018.1120 İndeks Tarihi: 29-07-2022

The Diagnostic and Prognostic Significance of MicroRNA-21 in Non-muscle Invasive Bladder Tumors

Öz:
Bladder cancer (BC) is one of the commonly diagnosed urological cancers that causes human death, ranked as the seventh most common cancerworldwide. To date, no reliable diagnostic tool has been defined to recognize non-muscle invasive bladder tumors other than cystoscopy. For thisreason, scientists have focused on finding new non-invasive biomarkers that can be used to diagnose BC with higher specificity and sensitivity. Thepurpose of this study was to evaluate the diagnostic role and prognostic significance of microRNA-21 (miR-21) in non-muscle invasive bladder tumors.In this review, the overall diagnostic performance of miR-21 was discussed on non-invasive BC based on a literature search of PubMed and CochraneLibrary. Although findings are insufficient, promising results have been reported regarding circulating miR-21 as a biomarker for BC prospectivestudies with larger numbers of participants are needed.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. V1.0. International Agency for Research on Cancer 2012.
  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
  • Malats N, Real FX. Epidemiology of bladder cancer. Hematol Oncol Clin North Am 2015;29:177-189.
  • Chavan S, Bray F, Lortet-Tieulent J, et al. International variations in bladder cancer incidence and mortality. Eur Urol 2014;66:59-73.
  • Sanguedolce F, Bufo P, Carrieri G, Cormio L. Predictive markers in bladder cancer: do we have molecular markers ready for clinical use? Crit Rev Clin Lab Sci 2014;51:291-304.
  • Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
  • Matsuda T, Hori M. Five-year relative survival rate of bladder cancer in the USA, Europe and Japan. Jpn J Clin Oncol 2014;44:776.
  • Goodison S, Rosser CJ, Urquidi V. Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests. Mol Diagn Ther 2013;17:71-84.
  • Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009;374:239-249.
  • Arcangeli G, Arcangeli S, Strigari L. A systematic review and metaanalysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC). Crit Rev Oncol Hematol 2015;94:105-115.
  • Messing EM. Urothelial tumors of the bladder. In: Wein AJ, Kavoussi LR, Novick AC, et al, eds. Campbell-Walsh urology. 9th ed. Philadelphia: Saunders; 2007. p. 2426-2427.
  • Smith ZL, Guzzo TJ. Urinary markers for bladder cancer. F1000Prime Rep 2013;5:21.
  • Shelley MD, Mason MD, Kynaston H. Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat Rev 2010;36:195-205.
  • Wu TT, Chen JH, Lee YH, Huang JK. The role of bcl-2, p53, and ki- 67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol 2000;163:758-760.
  • Quan C, Park MS, Jo SW, et al. Effects of transforming growth factor-beta1 and its receptor on the development, recurrence and progression of human bladder cancer. Korean J Urol 2006;47:426-435.
  • Ha YS, Yun SJ, Kim YJ, et al. Utility of Smo as a prognostic marker for human bladder tumors. Korean J Urol 2007;48:997-1003.
  • Tetu B. Diagnosis of urothelial carcinoma from urine. Mod Pathol 2009;22(Suppl 2):53-59.
  • Nakamura K, Kasraeian A, Iczkowski KA, et al. Utility of serial urinary cytology in the initial evaluation of the patient with microscopic hematuria. BMC Urol 2009;9:12.
  • Grossman HB, Soloway M, Messing E, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 2006;295:299-305.
  • Parker J, Spiess PE. Current and emerging bladder cancer urinary biomarkers. Scientific World Journal 2011;11:1103-1112.
  • Todenhöfer T, Hennenlotter J, Guttenberg P, et al. Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer. BMC Cancer 2015;15:155.
  • Miremami J, Kyprianou N. The promise of novel molecular markers in bladder cancer. Int J Mol Sci 2014;15:23897-23908.
  • Chao D, Freedland SJ, Pantuck AJ, et al. Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma. Rev Urol 2001;3:85-93.
  • Ebert MS, Sharp PA. Roles for microRNAs in conferring robustness to biological processes. Cell 2012;149:515-524.
  • Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell 2005;122:6-7.
  • Lieberman J, Slack F, Pandolfi PP, et al. Noncoding RNAs and cancer. Cell 2013;153:9-10.
  • Zhang DZ, Lau KM, Chan ES, et al. Cell-free urinary microRNA-99a and microRNA-125b are diagnostic markers for the non-invasive screening of bladder cancer. Plos One 2014;9:e100793.
  • Jiang X, Du L, Wang L, et al. Serum microRNA expression signatures identified from genomewide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer. Int J Cancer 2015;136:854-862.
  • Tölle A, Jung M, Rabenhorst S, et al. Identification of microRNAs in blood and urine as tumour markers for the detection of urinary bladder cancer. Oncol Rep 2013;30:1949-1956.
  • Mengual L, Lozano JJ, Ingelmo-Torres M, et al. Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer. Int J Cancer 2013;133:2631-2641.
  • Adam L, Wszolek MF, Liu CG, et al. Plasma microRNA profiles for bladder cancer detection. Urol Oncol 2013;31:1701-1708.
  • Miah S, Dudziec E, Drayton RM, et al. An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer. Br J Cancer 2012;107:123-128.
  • Snowdon J, Boag S, Feilotter H, Izard J, Siemens DR. A pilot study of urinary microRNA as a biomarker for urothelial cancer. Can Urol Assoc J 2013;7:28-32.
  • Zhou X, Zhang X, Yang Y, et al. Urinary cell-free microRNA-106b as a novel biomarker for detection of bladder cancer. Med Oncol 2014;31:197. Dietrich D, Meller S, Uhl B, et al. Nucleic acid-based tissue biomarkers of urologic malignancies. Crit Rev Clin Lab Sci 2014;51:173-199.
  • Shukla GC, Singh J, Barik S. MicroRNAs: Processing, Maturation, Target Recognition and Regulatory Functions. Mol Cell Pharmacol 2011;3:83-92.
  • Ma W, Yu Q, Jiang J, et al. miR-517a is an independent prognostic marker and contributes to cell migration and invasion in human colorectal cancer. Oncol Lett 2016;11:2583-2589.
  • Hu JY, Yi W, Wei X, et al. miR-601 is a prognostic marker and suppresses cell growth and invasion by targeting PTP4A1 in breast cancer. Biomed Pharmacother 2016;79:247-253.
  • Jiang LP, Zhu ZT, He CY. Expression of miRNA-26b in the diagnosis and prognosis of patients with non-small-cell lung cancer. Future Oncol 2016;12:1105-1115.
  • Wang F, Chang JT, Kao CJ, Huang RS. High expression of miR-532-5p, a tumor suppressor, leads to better prognosis in ovarian cancer both in vivo and in vitro. Mol Cancer Ther 2016;15:1123-1131.
  • Tilki D, Burger M, Dalbagni G, et al. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol 2011;60:484-492.
  • Cortez MA, Bueso-Ramos C, Ferdin J, et al. MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011;8:467-477.
  • Ord JJ, Agrawal S, Thamboo TP, et al. An investigation into the prognostic significance of necrosis and hypoxia in high grade and invasive bladder cancer. J Urol 2007;178:677-682.
  • Blick C, Ramachandran A, McCormick R, et al. Identification of a hypoxia-regulated miRNA signature in bladder cancer and a role for miR-145 in hypoxia-dependent apoptosis. Br J Cancer 2015;113:634-644.
  • Papagiannakopoulos T, Shapiro A, Kosik KS. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res 2008;68:8164-8172.
  • Lu Z, Liu M, Stribinskis V, et al. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 2008;27:4373-4379.
  • Liu LZ, Li C, Chen Q, et al. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1α expression. PLoS ONE. 2011;6:19139.
  • Zhang X, Zhang Y, Liu X, et al. Direct quantitative detection for cellfree miR-155 in urine: a potential role in diagnosis and prognosis for nonmuscle invasive bladder cancer. Oncotarget 2016;7:3255-3266.
  • Zhang X, Zhang Y, Liu X, et al. MicroRNA-203 Is a Prognostic Indicator in Bladder Cancer and Enhances Chemosensitivity to Cisplatin via Apoptosis by Targeting Bcl-w and Survivin. Plos One 2015;10:e0143441.
  • Wang J, Zhang X, Wang L, et al. MicroRNA-214 suppresses oncogenesis and exerts impact on prognosis by targeting PDRG1 in bladder cancer. PLoS One 2015;10:e0118086.
  • Kiemeney LA, Sulem P, Besenbacher S, et al. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet 2010;42:415-419.
  • Musavi SM, Mansoori B, Mohammadi A, et al. SiRNA-mediated silencing of Snail-1 induces apoptosis and alters micro RNA expression in human urinarybladder cancer cell line. Artif Cells Nanomed Biotechnol 2017;45:969-974.
  • Lei M, Xie W, Sun E, et al. microRNA-21 Regulates Cell Proliferation and Migration and Cross Talk with PTEN and p53 in Bladder Cancer. DNA Cell Biol 2015;34:626-632.
  • Wang Y, Gao X, Wei F, et al. Diagnostic and prognostic value of circulating miR-21 for cancer: a systematic review and meta-analysis. Gene 2014;533:389-397.
  • Kishimoto T, Eguchi H, Nagano H, et al. Plasma miR-21 is a novel diagnostic biomarker for biliary tract cancer. Cancer Sci 2013;104:1626-1631.
  • Kotb S, Mosharafa A, Essawi M, et al. Circulating miRNAs 21 and 221 as biomarkers for early diagnosis of prostate cancer. Tumour Biol 2014;35:12613-12617.
  • Caramés C, Cristóbal I, Moreno V, et al. MicroRNA-21 predicts response to preoperative chemoradiotherapy in locally advanced rectal cancer. Int J Colorectal Dis 2015;30:899-906.
  • Zhang HH, Qi F, Cao YH, et al. Expression and clinical significance of microRNA-21, maspin and vascular endothelial growth factor-C in bladder cancer. Oncol Lett 2015;10:2610-2616.
  • Zhang HH, Qi F, Cao YH, et al. Expression and clinical significance of microRNA-21, maspin and vascular endothelial growth factor-C in bladder cancer. Oncol Lett 2015;10:2610-2616.
  • Mitash N, Agnihotri S, Tiwari S, Agrawal V, Mandhani A. MicroRNA-21 could be a molecular marker to predict the recurrence of nonmuscle invasive bladder cancer. Indian J Urol 2017;33:283-290.
  • Morata Tarifa C, Jiménez G, García MA, et al. Low adherent cancer cell subpopulations are enriched in tumorigenic and metastatic epithelial to mesenchymal transition induced cancer stem like cells. Sci Rep 2016;6:18772.
  • Wszolek MF, Rieger-Christ KM, Kenney PA, et al. A MicroRNA expression profile defining the invasive bladder tumor phenotype. Urol Oncol 2011;29:794-801.
  • Neely LA, Rieger-Christ KM, Neto BS, et al. A microRNA expression ratio defining the invasive phenotype in bladder tumors. Urol Oncol 2010;28:39-48.
  • Tao J, Lu Q, Wu D, et al. microRNA-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells. Oncol Rep 2011;25:1721-1729.
APA çinar ö, Mungan N (2019). The Diagnostic and Prognostic Significance of MicroRNA-21 in Non-muscle Invasive Bladder Tumors. , 30 - 33. 10.4274/uob.galenos.2018.1120
Chicago çinar önder,Mungan Necmettin Aydın The Diagnostic and Prognostic Significance of MicroRNA-21 in Non-muscle Invasive Bladder Tumors. (2019): 30 - 33. 10.4274/uob.galenos.2018.1120
MLA çinar önder,Mungan Necmettin Aydın The Diagnostic and Prognostic Significance of MicroRNA-21 in Non-muscle Invasive Bladder Tumors. , 2019, ss.30 - 33. 10.4274/uob.galenos.2018.1120
AMA çinar ö,Mungan N The Diagnostic and Prognostic Significance of MicroRNA-21 in Non-muscle Invasive Bladder Tumors. . 2019; 30 - 33. 10.4274/uob.galenos.2018.1120
Vancouver çinar ö,Mungan N The Diagnostic and Prognostic Significance of MicroRNA-21 in Non-muscle Invasive Bladder Tumors. . 2019; 30 - 33. 10.4274/uob.galenos.2018.1120
IEEE çinar ö,Mungan N "The Diagnostic and Prognostic Significance of MicroRNA-21 in Non-muscle Invasive Bladder Tumors." , ss.30 - 33, 2019. 10.4274/uob.galenos.2018.1120
ISNAD çinar, önder - Mungan, Necmettin Aydın. "The Diagnostic and Prognostic Significance of MicroRNA-21 in Non-muscle Invasive Bladder Tumors". (2019), 30-33. https://doi.org/10.4274/uob.galenos.2018.1120
APA çinar ö, Mungan N (2019). The Diagnostic and Prognostic Significance of MicroRNA-21 in Non-muscle Invasive Bladder Tumors. Üroonkoloji Bülteni, 18(1), 30 - 33. 10.4274/uob.galenos.2018.1120
Chicago çinar önder,Mungan Necmettin Aydın The Diagnostic and Prognostic Significance of MicroRNA-21 in Non-muscle Invasive Bladder Tumors. Üroonkoloji Bülteni 18, no.1 (2019): 30 - 33. 10.4274/uob.galenos.2018.1120
MLA çinar önder,Mungan Necmettin Aydın The Diagnostic and Prognostic Significance of MicroRNA-21 in Non-muscle Invasive Bladder Tumors. Üroonkoloji Bülteni, vol.18, no.1, 2019, ss.30 - 33. 10.4274/uob.galenos.2018.1120
AMA çinar ö,Mungan N The Diagnostic and Prognostic Significance of MicroRNA-21 in Non-muscle Invasive Bladder Tumors. Üroonkoloji Bülteni. 2019; 18(1): 30 - 33. 10.4274/uob.galenos.2018.1120
Vancouver çinar ö,Mungan N The Diagnostic and Prognostic Significance of MicroRNA-21 in Non-muscle Invasive Bladder Tumors. Üroonkoloji Bülteni. 2019; 18(1): 30 - 33. 10.4274/uob.galenos.2018.1120
IEEE çinar ö,Mungan N "The Diagnostic and Prognostic Significance of MicroRNA-21 in Non-muscle Invasive Bladder Tumors." Üroonkoloji Bülteni, 18, ss.30 - 33, 2019. 10.4274/uob.galenos.2018.1120
ISNAD çinar, önder - Mungan, Necmettin Aydın. "The Diagnostic and Prognostic Significance of MicroRNA-21 in Non-muscle Invasive Bladder Tumors". Üroonkoloji Bülteni 18/1 (2019), 30-33. https://doi.org/10.4274/uob.galenos.2018.1120